[Current developments and perspectives in targeted therapies].
Many different approaches for improving the prognosis of patients with advanced non-small-cell lung cancer (NSCLC) are currently being investigated. This article discusses the significance of maintenance therapy after primary chemotherapy and reviews study data on second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), inhibitors of insulin-like growth factor receptors (IGFR), vascular-disrupting agents (VDAs) and multi-TKIs of vascular endothelial growth factor receptors (VEGFR). The article also looks at the future prospects of using genetic markers in the field of NSCLC.
Dickgreber
Nicolas
N
Klinik für Pneumologie, Medizinische Hochschule Hannover, Deutschland.
Huber
Rudolf M
RM
Reck
Martin
M
Reinmuth
Niels
N
Schütte
Wolfgang
W
Serke
Monika
M
Wolf
Jürgen
J
D000359:Aftercare; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics; D004252:DNA Mutational Analysis; D016503:Drug Delivery Systems; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000009:adverse effects; D066246:ErbB Receptors / Q000032:analysis* / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics; D009367:Neoplasm Staging; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases; D017451:Receptors, Somatomedin / Q000037:antagonists & inhibitors / Q000235:genetics; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000235:genetics
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D005819:Genetic Markers; D015514:Oncogene Proteins, Fusion; D017451:Receptors, Somatomedin; D000077548:Anaplastic Lymphoma Kinase; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor